Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
646
datasets available to search
ShareScore release 0.9.0
Dataset results
646 results for “Clinical data”
Clinical data of COVID-19 infected patients
<p>Objectives</p> <p>This study aimed to evaluate the clinical efficacy of Paxlovid in patients hospitalized with severe/critical COVID-19.</p> <p>Methods</p> <p>Data were acquired from patients with severe/critical COVID-19 diagnosed between December 2022 and January 2023 at a medical center in China. Patients were divided into the Paxlovid treatment group and the conventional treatment group. The association between Paxlovid and all-cause mortality of patients during hospitalization was evaluated using the COX regression model and inverse probability weighting method, respectively. The secondary endpoint was the improvement in patients' lung imaging findings 1 week later. The odds ratio (OR) was estimated using logistic regression.</p> <p>Results</p> <p>A total of 158 eligible patients were enrolled, including 50 in-hospital deaths (50/98) in the Paxlovid group and 28 (28/60) in the conventional treatment group. The corrected hazard ratio for death was 0.51 (95% CI: 0.28–0.94, p = 0.031) and the inverse probability-weighted hazard ratio was 0.42 (95% CI: 0.24–0.75). The secondary endpoint analysis revealed that Paxlovid was associated with improved lung imaging findings 1 week later (adjusted OR: 0.35, 95% CI: 0.16–0.77).</p> <p>Conclusion</p> <p>Treatment with Paxlovid is associated with a significantly reduced risk of death and improved lung imaging findings in patients with severe/critical COVID-19.</p>
Continuous Digital Monitoring of Walking Speed in Frail Elderly Patients: Noninterventional Validation Study and Longitudinal Clinical Trial (Data for interventional clinical trial)
<p>Digital technologies and advanced analytics have drastically improved our ability to capture and interpret health relevant data from patients. However, to date, limited data and results have been published detailing real-world patient compliance, demonstrating accuracy in target indications or examining what novel insights and clinical value can be derived. Here we present novel, digital mobility data from two studies: an independent, non-interventional validation study with elderly, naturally slow walking subjects, and a global, multi-site phase IIb clinical trial involving patients with age-related muscle loss and slow walking speed (sarcopenia). Based on these data, we validate the accuracy of a novel algorithm for capturing in-clinic and real-world gait speed in frail, slow-walking adults. We demonstrate the feasibility of continuous monitoring with a wearable inertial sensor in elderly adults in real-world settings, and propose minimum thresholds for compliance required for robust capture of gait behaviors in this population. We also show how simple, inferred contextual information, describing the length of a given walking bout, can explain some of the variation in real-world gait speed, and use this information to demonstrate for the first time a relationship between in-clinic performance and real-world gait speed behavior. This work lays a foundation for exploration of the clinical relevance and value of such measures and is a first step in building a more complete chain of evidence between standardized physical performance assessment, real-world behavior, and subjective perceptions of mobility, independence and health.</p> <p>This dataset contains data collected during the interventional clinical trial: derived data from raw accelerometry data, and summary performance data.</p> <p>The full dataset, including raw accelerometry data, is available here: <a href="https://mueller-et-al-2019.s3.amazonaws.com/index.html">https://mueller-et-al-2019.s3.amazonaws.com/index.html</a></p>
Data for: Communicating with deaf patients in the clinical environment: Lessons learned from a virtual patient panel
Open the record for dataset details and reuse information.
Data from: Perioperative medication management: expanding the role of the preadmission clinic pharmacist in a single centre, randomised controlled trial of collaborative prescribing
Objectives: Current evidence to support non-medical prescribing is predominantly qualitative, with little evaluation of accuracy, safety and appropriateness. Our aim was to evaluate a new model of service for the Australia healthcare system, of inpatient medication prescribing by a pharmacist in an elective surgery pre admission clinic (PAC) against usual care, using an endorsed performance framework. Design: Single centre, randomised controlled, two arm trial Setting: Elective surgery pre admission clinic in Brisbane based tertiary hospital Participants: Four hundred adults scheduled for elective surgery were randomised to intervention or control. Intervention: A pharmacist generated the inpatient medication chart to reflect the patient's regular medication, made a plan for medication perioperatively and prescribed VTE prophylaxis. In the control arm, the medication chart was generated by the Resident Medical Officers (RMO). Outcome Measures: Primary outcome was frequency of omissions and prescribing errors when compared against the medication history. The clinical significance of omissions was also analysed. Secondary outcome was appropriateness of VTE prophylaxis prescribing. Results: There were significantly less unintended omissions of medications: 11 of 887 (1.2%) intervention orders compared with 383 of 1217 (31.5%) control (p<0.001). There were significantly less prescribing errors involving selection of drug, dose or frequency: 2 in 857 (0.2%) intervention orders compared with 51 in 807 (6.3%) control (p<0.001). Orders with at least one component of the prescription missing, incorrect or unclear occurred in 20826 of 904 (235%) intervention orders and 445667 of 1034 (4364.5%) control (p<0.001). VTE prophylaxis on admission to the ward was appropriate in 93% of intervention patients and 90% control (p=0.29). Conclusion: Medication charts in the intervention arm contained fewer clinically significant omissions, and prescribing errors, when compared to control. There was no difference in appropriateness of VTE prophylaxis on admission between the two groups. Trial Registration: Registered with ANZCTR – ACTR Number ACTRN12609000426280
Data from: Clinical efficacy of implantation of toric intraocular lenses with different incision positions: a comparative study of steep-axis incision and non-steep-axis incision
Background: To compare the clinical outcomes after implantation of AcrySof Toric IOLs with different clear corneal incisions. Methods: Sixty cataract patients with regular corneal astigmatism who underwent phacoemulsification combined with implantation of an AcrySof Toric IOL were enrolled. They were divided into two groups according to the position of the clear corneal incision: steep-axis and non-steep-axis. Main outcome measurements included visual acuity, residual astigmatism and changes of corneal astigmatism 3 months postoperatively. Deviation of IOL axis according to the re-calculation using the actual surgically induced astigmatism (SIA) and visual function 3 months after surgery were also evaluated. Results: The corneal astigmatism decreased significantly in steep-axis group 3 months postoperatively (P < 0.05). Besides, more patients in non-steep-axis group were with irregular corneal astigmatism after the surgery (43.33% vs 10%, P = 0.004). The deviation of IOL axis according to the re-calculation using the actual SIA was significantly larger in non-steep-axis group than that of steep-axis group (P < 0.001). Moreover, the postoperative visual function was better in eyes of steep-axis group in various measurements, including point spread function, modulation transfer function and high-order aberrations. Conclusion: Steep-axis clear corneal incision could reduce the cylinder power of toric IOL and lower the chance of postoperative irregular astigmatism, which may consequently improve the postoperative visual quality.
Gene alterations, clinical informations and survival data of gliomas with/without corpus callosum involvement
<p>The raw dataset of this study contained the gene alterations, clinical informations and survival data of glioma patients. Gene alterations data were obtained by Next-generation DNA sequencing of glioma samples of patients. Clinical informations were obtained from Electronic medical records and follow-up. The survival data were obtained by follow-up of patients. In order to explore gene alterations and their correlation with the survival of glioblastoma (GBM) of corpus callosum (CC) involvement (ccGBM), this dataset was analyzed in detail. A total of<b> </b>30 ccGBM and 88 non-ccGBM were finally included. The ccGBM had higher incidence of <i>PDGFRA </i>(33.3% versus 9.1%, P=0.004) alterations than non-ccGBM. <i>PDGFRA </i>amplification (<i>PDGFRAamp</i>, 33.3% versus 9.1%, P=0.004) and missense mutation (<i>PDGFRAmut</i>, 20.0% versus 3.4%, P=0.011) both had higher incidence in ccGBM than in non-ccGBM. <i>PDGFRA </i>alteration was significantly associated with the occurrence of ccGBM (OR=4.91 [95%CI: 1.55-15.52], P=0.007). The ccGBM of <i>PDGFRAamp </i>achieved shorter median PFS (8.6 versus 13.5 months, P=0.025) and OS (12.4 versus 17.9 months, P=0.022) than non-ccGBM of <i>PDGFRAnon-amp</i>. The ccGBM of <i>PDGFRAamp</i> combined with <i>PDGFRAmut</i> (<i>PDGFRAamp-mut</i>)<i> </i>had shorter median PFS (7.6 versus 8.9 months, P=0.022) and OS (9.6 versus 17.8 months, P=0.006) than non-ccGBM of <i>PDGFRA</i> wild type and non-amplification (<i>PDGFRA-w, non-amp</i>). Compared to ccGBM of <i>PDGFRA-w, non-amp</i>, the ccGBM of <i>PDGFRAamp</i> and <i>PDGFRAamp-mut </i>both had shorter median PFS and OS (P<0.05). Hazard ratios (HRs) of <i>PDGFRAamp</i> for PFS and OS of ccGBM were 3.08 (95%CI: 1.02-9.35, P=0.047) and 5.07 (95%CI: 1.52-16.89, P=0.008) respectively, HRs of <i>PDGFRAamp-mut </i>for PFS and OS were 13.16 (95%CI: 3.19-54.40, P<0.001) and 16.36 (95%CI: 2.66-100.70, P=0.003) respectively. The <i>PDGFRA </i>alterations is significantly associated with the occurrence and poor prognosis of ccGBM.</p>
Extended data for: Screening for antifolate and artemisinin resistance in Plasmodium falciparum clinical isolates from three hospitals of Eritrea
<p><i>Background</i>: Antimalarial drug resistance is a major challenge hampering malaria control and elimination. <i>Plasmodium falciparum</i>, the leading causative parasite species, has developed resistance to basically all antimalarials. Continued surveillance of drug resistance using genetic markers provides important molecular data for treatment policies. This study sought to verify the genetic mechanism of resistance to sulfadoxine-pyrimethamine and assess the occurrence of point mutations associated with artemisinin resistance in <i>P. falciparum</i> clinical isolates from Eritrea.</p> <p><i>Methods</i>: Nineteen dried blood spot samples were collected from patients visiting Adi Quala, Keren and Gash Barka Hospitals, Eritrea. The patients were followed up after receiving treatment with first line artesunate-amodiaquine. Nested polymerase chain reaction and Sanger sequencing techniques were employed to genotype point mutations in the <i>P. falciparum</i> bifunctional dihydrofolate reductase-thymidylate synthase (<i>Pfdhfr</i>, PF3D7_0417200), dihydropteorate synthase (<i>Pfdhps</i>, PF3D7_0810800) and kelch 13 (<i>PfK13</i>, PF3D7_1343700) genes.</p> <p><i>Results</i>: Eight of nineteen (42%) of the dried blood spot samples were successful for PCR-amplification. Data analyses of the PCR-positive isolates revealed the following point mutations: <i>Pfdhfr </i>N51I in four isolates, C59R in one isolate, S108N in four isolates, a rare non-synonymous substitution V45A in four isolates and <i>Pfdhps</i> K540E in four isolates. No <i>PfK13</i> point mutations were reported.</p> <p><i>Conclusions</i>: <i>Pfdhfr</i> C59R and <i>Pfdhps</i> K540E point mutations are reliable markers for the sulfadoxine-pyrimethamine quintuple mutant haplotype combination. These findings highlight first reports in Eritrea, which verify the underlying genetic mechanism of antifolate resistance. Continuous monitoring of the <i>PfK13</i> marker is recommended.</p>
Data from: Clinical spectrum of CANVAS
<p><span><b>Objective: </b>To elucidate the clinical significance of an intronic biallelic pentanucleotide repeat expansion in the gene encoding Replication Factor C subunit 1<i> (RFC1)</i> in patients with late-onset Cerebellar Ataxia, Neuropathy and Vestibular Areflexia Syndrome (CANVAS), other ataxias and in healthy controls by comprehensive genetic analyses.</span></p> <p><span><b>Methods:</b> In this case-control study, we included 457 individuals comprising 26 patients with complete or incomplete CANVAS, 70 patients with late-onset cerebellar ataxia, 208 healthy controls and 153 individuals from 39 multigenerational non-ataxia families to determine repeat stability. All 96 patients were screened for the repeat expansion by duplex PCR. To further characterize the repeat type and lengths, we used fragment length analysis, repeat-primed PCR, Sanger sequencing, and Southern blotting. Expression of <i>RFC1</i> and the neighboring gene <i>WDR19</i> were determined by quantitative PCR. </span></p> <p><span><b>Results:</b> Massive biallelic pentanucleotide expansions were found in 15/17 complete CANVAS patients (88%), in 2/9 (22%) with incomplete CANVAS, in 4/70 (6%) patients with unspecified, late-onset cerebellar ataxia, but not in controls. In patients, the expansion comprised 800-1,000 mostly AAGGG repeats. Non-massively expanded repeat numbers were in the range of 7 to 137 repeats and relatively stable during transmission. Expression of <i>RFC1</i> and <i>WDR19</i> were unchanged and <i>RFC1</i> intron retention was not found.</span></p> <p><b>Conclusions:</b> A biallelic pentanucleotide repeat expansion is a frequent cause of CANVAS and found in a considerable number of patients with an incomplete clinical presentation or other forms of cerebellar ataxia. The mechanism by which the repeat expansions are causing disease remains unclear and warrants further investigations.</p>
Figure 2 from: Klein A, Ghosh S (2016) Graph-based clinical diagnosis and prediction using multi-modal neuroimaging data. Research Ideas and Outcomes 2: e8835. https://doi.org/10.3897/rio.2.e8835
Figure 2 - Examples of automatically extracted features (MRI) (a) Example structural features (left lateral views of volumes, surfaces, curves, and points) (b) Schematic feature hierarchy: 3-D gyrii surround a 2-D sulcal ribbon with 1-D fundus containing 0-D pits
Figure 1 from: Klein A, Ghosh S (2016) Graph-based clinical diagnosis and prediction using multi-modal neuroimaging data. Research Ideas and Outcomes 2: e8835. https://doi.org/10.3897/rio.2.e8835
Figure 1 - Examples of graph-based representations of scientific data among hundreds on the www.visualcomplexity.com website (categories on the site include biology, food webs and semantic, social, and knowledge networks). Lower left images of DTI, connectome, and network hubs are from Olaf Sporns (2010, Scholarpedia, 5(2):5584).
Figure 3 from: Klein A, Ghosh S (2016) Graph-based clinical diagnosis and prediction using multi-modal neuroimaging data. Research Ideas and Outcomes 2: e8835. https://doi.org/10.3897/rio.2.e8835
Figure 3 - Example of a graph-based representation of MRI and DTI features (a) A gray/white matter surface (left lateral view) with (visible) sulcal pits highlighted. These features go by different names (sulcal roots, buried gyrii, annectant gyrii, plis de passage) and may be well conserved structures formed early in development. (b) DTI connectivity graph computed on the same patient with depression as on the left panel. Vertices represent automatically extracted sulcal pits and each edge indicates a connection probability greater than 0.01 between two vertices.
Raw Data for the article: Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial
<p><strong>Background: </strong>The current curative approaches for ischemia/reperfusion injury on liver transplantation are still under debate for their safety and efficacy in patients with end-stage liver disease. We present the SIMVA statin donor treatment before Liver Transplants study.</p> <p><strong>Methods: </strong>SIMVA statin donor treatment before Liver Transplants is a monocentric, double-blind, randomized, prospective tial aiming to compare the safety and efficacy of preoperative brain-dead donors' treatment with the intragastric administration of 80 mg of simvastatin on liver transplant recipient outcomes in a real-life setting. Primary aim was incidence of patient and graft survival at 90 and 180 d posttransplant; secondary end-points were severe complications.</p> <p><strong>Results: </strong>The trial enrolled 58 adult patients (18-65 y old). The minimum follow-up was 6 mo. No patient or graft was lost at 90 or 180 d in the experimental group (n = 28), whereas patient/graft survival were 93.1% ( P = 0.016) and 89.66% ( P = 0.080) at 90 d and 86.21% ( P = 0.041) and 86.2% ( P = 0.041) at 180 d in the control group (n = 29). The percentage of patients with severe complications (Clavien-Dindo ≥IIIb) was higher in the control group, 55.2% versus 25.0% in the experimental group ( P = 0.0307). The only significant difference in liver tests was a significantly higher gamma-glutamyl transferase and alkaline phosphatase at 15 d ( P = 0.017), ( P = 0.015) in the simvastatin group.</p> <p><strong>Conclusions: </strong>Donor simvastatin treatment is safe, and may significantly improve early graft and patient survival after liver transplantation, although further research is mandatory.</p>
Compendium of primary head and neck cancer gene expression datasets with accompanying clinical data
<p>We assembled a compendium of 30 primary HNC gene expression datasets with accompanying clinical data, representing the largest such resource for HNC. This resource was specifically built to identify genes associated with two outcome variables: patient survival and lymph node metastasis (LNM) status. Meta-analyses were applied to uniformly preprocessed gene expression data, as in our PRECOG resource (Gentles et al, Nat Med, 2016). Briefly, datasets were quality controlled, normalized, log transformed, and standardized to calculate gene expression profiles. Clinical data were manually curated and included survival and LNM status as well as variables relevant to HNC prognosis, such as tumor grade, tumor subanatomic location, and HPV status. The resulting 30 cleaned studies included 2,134 HNC tumors. 1,666 patients (across 17 cohorts) had survival outcome data and 1,490 patients (21 cohorts) had LNM status. Fully processed datasets are provided here as a resource to enable efficient meta-analyses of gene expression data in head and neck cancer.</p>
Table for original data on clinical characteristics of the two cohorts.
<p>This table includes original data on clinical characteristics of the two cohorts.</p>
Clinical Characteristics and Prognosis of STEMI Patients Undergoing Primary Percutaneous Coronary Angioplasty and Angiographic Data
ClinicalTrials.gov study NCT05679843. IPD Sharing: NO. Countries: 0. Publications: 1.
PMCF Study on the Safety, Performance and Clinical Benefits Data of the ToggleLoc™ 2.9mm and JuggerLoc™ in the Shoulder
ClinicalTrials.gov study NCT05584553. IPD Sharing: NO. Countries: 2. Publications: 0.
Demographic Data and Clinical Presentation of Pediatric Uveitis
ClinicalTrials.gov study NCT06920017. IPD Sharing: Not stated. Countries: 0. Publications: 9.
PMCF Study on the Safety, Performance and Clinical Benefits Data of the ToggleLoc™ 2.9mm in the Elbow
ClinicalTrials.gov study NCT05519228. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Generate Real World Data On Tofacitinib Induction Therapy and Changes In Clinical and Patient Reported Outcomes.
ClinicalTrials.gov study NCT05069259. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study to Investigate the Association of Real-world Sensor-derived Biometric Data With Clinical Parameters and Patient-reported Outcomes for Monitoring Disease Activity in Patients With COPD
ClinicalTrials.gov study NCT05655832. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.